Skip to content

Acquirer · Listed strategic

Novanta

A US technology group buying its way deeper into medical and life sciences OEM supply, with a clear direction of travel but no published screening criteria.

United States
Headquarters
Photonics, vision and precision motion for medical and advanced industrial OEMs
Focus
Private
Listing

At a glance

Type
Listed strategic acquirer
Core capabilities
Photonics, vision and precision motion
End markets sought
Medical and advanced industrial OEMs, weighted to medical and life sciences
Stated direction
Towards more durable, recurring revenue and reduced cyclicality
Deal range
From around $189m for Motion Solutions to $1.2bn for Riverpoint Medical
Published criteria
None located. The direction is clear from the deal record, the test is not published

How Novanta buys

Novanta describes itself as a supplier of core technology to medical and advanced industrial OEMs, with proprietary expertise in photonics, vision and precision motion. Its acquisitions have consistently pushed the mix towards medical and life sciences, and its management has framed the strategy as shifting towards more durable, recurring revenue, which reduces cyclicality and deepens medical OEM partnerships.

What it does not publish is a screen. There is no stated size band, margin threshold or return hurdle in the material we located, so this entry records the direction of travel rather than inferring criteria the company has not set out. A seller should establish the test directly rather than reverse-engineering it from announcements.

The deal record does give the range and the pattern. World of Medicine at EUR 115 million in 2017 broadened medical end-market exposure; Motion Solutions at around $189 million in 2023 added precision motion subsystems for medical and life sciences OEMs; and Riverpoint Medical at around $1.2 billion is a different order of magnitude again. The 2021 purchases of Schneider Electric Motion and ATI Industrial Automation extended robotics and automation reach alongside that.

One structural point worth noting: Novanta has been willing to build a position rather than buy outright, having increased its stake in Laser Quantum to over 75 per cent rather than acquiring all of it at once. An owner open to a staged sale has a route here that an outright-only buyer would not offer.

Sources

  1. Novanta - announcement of the Riverpoint Medical acquisition
  2. Novanta - agreement to acquire Motion Solutions
  3. Novanta - increase in ownership of Laser Quantum

Facts last checked 9 November 2026. Public information only: spotted something out of date? It will be corrected with a dated note.